I somewhat share Baldwidx concerns that we may have a potential issue with NNZ-2591 development, being that we do not have complete control over what indications can be developed for NNZ-2591 on our own.From the NEU announcement 14/7/2023;
Neuren has an obligation not to develop NNZ-2591 or any other product for North America in an indication for which Acadia develops trofinetide, except for Phelan-McDermid, Pitt Hopkins, Angelman and Prader-Willi syndromes.
If Acadia decide to begin to developing trofinetide across an expansive range of syndromes how will that affect NNZ-2591's value?
I can't answer whether or not they can they do that, or whether they would they do that, or even if Acadia could afford to, however it certainly bares considering.
- Forums
- ASX - By Stock
- NEU
- ANAVEX MEETS ENDPOINTS PHASE2 RETT
ANAVEX MEETS ENDPOINTS PHASE2 RETT, page-138
-
- There are more pages in this discussion • 29 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$15.60 |
Change
-0.340(2.13%) |
Mkt cap ! $1.993B |
Open | High | Low | Value | Volume |
$16.25 | $16.32 | $15.55 | $9.440M | 595.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 3197 | $15.60 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$15.68 | 1852 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 3197 | 15.600 |
1 | 500 | 15.590 |
1 | 48 | 15.570 |
1 | 1000 | 15.550 |
2 | 1455 | 15.530 |
Price($) | Vol. | No. |
---|---|---|
15.680 | 1852 | 1 |
15.700 | 1455 | 2 |
15.710 | 4852 | 2 |
15.730 | 1000 | 1 |
15.740 | 1852 | 1 |
Last trade - 16.10pm 14/08/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |